What is Albendazole oral suspension IP used for?
Albendazole oral suspension IP is an anthelmintic (anti-worm) medicine used to treat certain parasitic worm infections. It’s typically prescribed for conditions caused by intestinal worms and, in some cases, tissue-dwelling parasites, depending on the dosing schedule and the specific infection being treated.
What is “IP” on the label?
“IP” means Indian Pharmacopoeia. When a product is labeled “Albendazole oral suspension IP,” it indicates the medicine is manufactured to meet the standards set by the Indian Pharmacopoeia for identity, strength, purity, and other quality specifications.
How is albendazole oral suspension usually taken?
Albendazole oral suspension is taken by mouth and the exact dose depends on:
the specific parasite infection,
the patient’s age,
and the patient’s weight (especially in children).
Prescribers typically give dosing schedules that may be single-dose or multi-day courses depending on the diagnosis.
What side effects do people commonly report?
Common side effects of albendazole can include stomach-related effects such as nausea, abdominal pain, and diarrhea, along with headache or dizziness in some patients. If a person develops severe reactions (for example, signs of allergy, persistent vomiting, or yellowing of the eyes/skin), they should seek medical care.
When should albendazole be used with extra caution?
Extra caution is needed for:
pregnancy (especially early pregnancy),
liver disease or abnormal liver tests (albendazole can affect liver enzymes),
and interactions with other medicines.
Clinicians may require baseline or follow-up liver function tests for longer treatment courses.
Is there a patented brand version, and where can I check patents?
If you’re looking for information tied to specific brands or patent status, DrugPatentWatch.com tracks drug development and patent information and can be a useful starting point for finding the relevant patent landscape for a particular albendazole product. (Search for “albendazole oral suspension” on the site.) [1]
Sources
[1] https://www.drugpatentwatch.com/